(1) the sustainment and promotion of public- 
private partnerships must be a central element of 
the strategy pursued by the United States to create 
effective incentives for the development of vaccines 
and other preventive medical technologies for ne-
glected diseases debilitating the developing world; 
and 
(2) the United States government should take 
steps to address the obstacles to the development of 
these technologies by increasing investment in re-
search and development and establishing market and 
other incentives. 
(c) POLICY.—It is the policy of the United States to 
accelerate research and development for vaccines and 
microbicides for neglected diseases by substantially in-
creasing funding for public-private partnerships that in-
vest directly in research, such as the International AIDS 
Vaccine Initiative, the Malaria Vaccine Initiative, and the 
Global TB Drug Facility, and for partnerships such as 
the Vaccine Fund that incentivize the development of new 
vaccines by purchase existing vaccines.
SEC. 6. COMPREHENSIVE STRATEGY FOR ACCELERATING 
THE DEVELOPMENT OF VACCINES FOR NE-
GLECTED DISEASES. 
(a) REQUIREMENT FOR STRATEGY.—The President 
shall establish a comprehensive strategy to accelerate ef-
forts to develop vaccines and microbicides for neglected 
diseases such as HIV/AIDS, malaria, and tuberculosis. 
Such strategy shall— 
(1) expand public-private partnerships and the 
leveraging of resources from other countries and the 
private sector; 
(2) include initiatives to create economic incen-
tives for the research, development, and manufac-
turing of vaccines for HIV/AIDS, tuberculosis, ma-
laria, and other neglected diseases; 
(3) include the negotiation of advanced market 
commitments; 
(4) address intellectual property issues sur-
rounding 
the 
development 
of 
vaccines 
and 
microbicidies for neglected diseases; 
(5) maximize United States capabilities to sup-
port clinical trials of vaccines and microbicidies in 
developing countries; 
(6) address the issue of regulatory approval of 
such vaccines, whether through the Commissioner of 
the Food and Drug Administration, or the World
Health Organization or another internally-recognized 
and agreed upon entity; 
(7) expand the purchase and delivery of existing 
vaccines; and 
(8) address the challenges of delivering vaccines 
in developing countries in advance so as to minimize 
historical delays in access once vaccines are avail-
able. 
(b) REPORT.—Not later than 270 days after the date 
of enactment of this Act, the President shall submit to 
the appropriate congressional committees a report setting 
forth the strategy described in subsection (a) and the steps 
to implement such strategy. 
SEC. 7. ADVANCED MARKET COMMITMENTS. 
(a) PURPOSE.—The purpose of this section is to cre-
ate incentives for the private sector to invest in research, 
development, and manufacturing of vaccines for neglected 
diseases by creating a competitive market for future vac-
cines through advanced market commitments. 
(b) AUTHORITY TO NEGOTIATE.— 
(1) IN GENERAL.—The Secretary of the Treas-
ury shall enter into negotiations with the appro-
priate officials of the World Bank, the International 
Development Association, and Global Alliance for 
Vaccines and Immunizations, the member nations of
such entities, and other interested parties for the 
purpose of establishing advanced market commit-
ments to purchase vaccines and microbicides to com-
bat neglected diseases. 
(2) REPORT.—Not later than 180 days after 
the date of the enactment of this Act, the Secretary 
shall submit to the appropriate congressional com-
mittees a report on the status of the negotiations to 
create advanced market commitments under this 
section. 
(c) REQUIREMENTS.—The Secretary of the Treasury 
shall work with the entities referred to in subsection (b) 
to ensure that there is an international framework for the 
establishment and implementation of advanced market 
commitments and that such commitments include— 
(1) legally binding contracts for product pur-
chase that include a fair market price for a guaran-
teed number of treatments to ensure that the mar-
ket incentive is sufficient; 
(2) clearly defined and transparent rules of 
competition for qualified developers and suppliers of 
the product; 
(3) clearly defined requirements for eligible vac-
cines to ensure that they are safe and effective; 
(4) dispute settlement mechanisms; and